This study tested an experimental oral drug called NG101 to see if it could reduce stomach-related side effects (like nausea and vomiting) caused by GLP-1 agonist weight-loss injections such as semaglutide. 120 healthy adults with a BMI between 22 and 35 took either NG101 or a pl…
Phase: PHASE2 • Sponsor: Neurogastrx, Inc. • Aim: Symptom relief
Last updated May 12, 2026 13:44 UTC